Mylan Inc. has introduced risperidone orally disintegrating tablets in strengths of 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.


Mylan, risperidone orally disintegrating tablets, Mylan Pharmaceuticals, Risperdal M-Tab, Risperdal generic, Ortho-McNeil, antipsychotic medication, schizophrenia, bipolar disorder


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan ships Risperdal generic

May 13th, 2011

PITTSBURGH – Mylan Inc. has introduced risperidone orally disintegrating tablets in strengths of 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg.

The company said Friday that the product, launched by its Mylan Pharmaceuticals Inc. subsidiary, is a generic version of Ortho-McNeil's Risperdal M-Tab, a treatment for schizophrenia.

Last year, risperidone orally disintegrating tablets had U.S. sales of approximately $61 million, according to IMS Health data provided by Mylan.

An antipsychotic medication, risperidone is used to treat schizophrenia and symptoms of bipolar disorder, or manic depression.

Advertisement